Zealand Pharma Welcomes New Senior Global Medical Advisor
In an exciting development for the team at Zealand Pharma, Steven R. Smith, MD, has been appointed as the Senior Global Medical Advisor in the field of obesity. This strategic addition is aimed at bolstering the research efforts within the company to address growing health care challenges related to obesity.
About Zealand Pharma and Its Mission
Zealand Pharma A/S (NASDAQ: ZEAL) is a dedicated biotechnology firm focused on discovering and developing innovative peptide-based medicines. Founded in 1998 and located in Copenhagen, Denmark, with additional operations in the U.S., Zealand Pharma is on a mission to create transformative treatments. With over ten drug candidates advancing into clinical stages, two have successfully reached the market, showcasing the company’s commitment to innovation.
Background of Steven R. Smith, MD
Joining Zealand as of January 1, 2025, Dr. Smith brings a wealth of experience spanning three decades in clinical and translational research, particularly in obesity, diabetes, and metabolism. His credentials are impressive, boasting over 300 scientific publications, which reflect his impactful contributions to the fields of metabolic health and obesity treatment.
Previous Roles and Contributions
Previously, Dr. Smith held the position of Chief Scientific Officer at the AdventHealth Research Institute. During this time, he spearheaded the strategic direction for research, enhancing the quality of care through innovative scientific approaches. His leadership in founding the Translational Research Institute exemplifies his dedication to translating research findings into practical clinical applications. Additionally, he has served as an adjunct professor at various esteemed institutions, further solidifying his expertise.
Future Directions in Obesity Research
During his statement, Dr. Smith expressed his enthusiasm for joining Zealand Pharma, highlighting the critical juncture in obesity research and the promising pipeline of differentiated assets the company possesses. He noted, "I am looking forward to working closely with my talented new colleagues and playing our part in addressing one of society’s biggest health care challenges.” This positive outlook underscores Zealand's future ambitions to develop effective treatments for obesity and other metabolic conditions.
Partnerships and Collaborations
Zealand Pharma has cultivated partnerships with numerous pharmaceutical companies, enhancing its capacity to bring innovative treatments to market. This collaborative spirit is vital for the success of its clinical development programs, broadening the access to and efficacy of its solutions against obesity and related health disorders.
Innovative Drug Candidates
The company has several drug candidates that are currently in late-stage development, signaling a robust pipeline poised to make significant impacts in the biotechnology landscape. As Zealand Pharma continues to explore novel peptide-based therapies, the expertise of professionals like Dr. Smith will be crucial in navigating the complexities of obesity treatment.
Contact Information
For further inquiries or to learn more about Zealand Pharma’s initiatives, interested parties can reach out to the Investor Relations team. Adam Lange, the Investor Relations Officer, can be contacted at alange@zealandpharma.com. Additionally, Neshat Ahmadi, the Investor Relations Manager, and Anna Krassowska, PhD, the Vice President of Investor Relations & Corporate Communications, are also available for media inquiries.
Frequently Asked Questions
What position has Steven R. Smith, MD, accepted at Zealand Pharma?
Steven R. Smith, MD, has joined Zealand Pharma as the Senior Global Medical Advisor focused on obesity.
What is Zealand Pharma known for?
Zealand Pharma is a biotechnology company that focuses on discovering and developing peptide-based medicines.
How many drug candidates has Zealand Pharma developed?
Zealand Pharma has advanced over 10 drug candidates into clinical development, with multiple candidates in late-stage development.
What experience does Dr. Smith bring to Zealand Pharma?
Dr. Smith has over 30 years of experience in obesity, diabetes, and metabolism research, contributing to more than 300 scientific publications.
How can someone get more information about Zealand Pharma?
For more information, individuals can contact Zealand Pharma's Investor Relations team via email.
